What is the price target for MAZE stock?
12 analysts have analysed MAZE and the average price target is 61.71 USD. This implies a price increase of 114.94% is expected in the next year compared to the current price of 28.71.
MAZE THERAPEUTICS INC (MAZE) Forecast, Price Target & Analyst Ratings
NASDAQ:MAZE • US5787841007
Current stock price
28.71 USD
-0.34 (-1.17%)
At close:
28.71 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MAZE THERAPEUTICS INC (MAZE).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q1 / 2026
- EPS Estimate
- -$0.55
- Revenue Estimate
- 10.201M
Price Target Details & History
Consensus Price Target and Range
Mean target
$61.71
Upside
+ 114.94%
From current price of $28.71 to mean target of $61.71, Based on 12 analyst forecasts
Low
$46.46
Median
$58.65
High
$101.85
Price Target Revisions
1 Month
19.51%
3 Months
39.88%
Price Target Summary
12 Wall Street analysts provided a forecast for the next 12 months for MAZE. The average price target is 61.71 USD. This implies a price increase of 114.94% is expected in the next year compared to the current price of 28.71.
The average price target has been revised upward by 39.88% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.67%
MAZE was analyzed by 12 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about MAZE.
In the previous month the buy percentage consensus was at a similar level.
MAZE was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-31 | JP Morgan | Maintains | Overweight -> Overweight |
| 2026-03-25 | BTIG | Reiterate | Buy -> Buy |
| 2026-03-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-03-18 | Truist Securities | Initiate | Buy |
| 2026-03-16 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-03-10 | Mizuho | Initiate | Outperform |
| 2026-03-09 | BTIG | Reiterate | Buy -> Buy |
| 2026-03-04 | Guggenheim | Maintains | Buy -> Buy |
| 2026-01-16 | BTIG | Maintains | Buy -> Buy |
| 2025-12-04 | Wells Fargo | Initiate | Overweight |
| 2025-12-03 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-07 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-09-29 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-15 | Guggenheim | Maintains | Buy -> Buy |
| 2025-09-12 | BTIG | Maintains | Buy -> Buy |
| 2025-09-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-11 | BTIG | Maintains | Buy -> Buy |
| 2025-09-02 | BTIG | Initiate | Buy |
| 2025-07-23 | HC Wainwright & Co. | Initiate | Buy |
| 2025-07-08 | Wedbush | Initiate | Outperform |
| 2025-04-02 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-02-25 | Leerink Partners | Initiate | Outperform |
| 2025-02-25 | Guggenheim | Initiate | Buy |
| 2025-02-25 | JP Morgan | Initiate | Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q1 / 2026
- EPS Estimate
- -$0.55
- Revenue Estimate
- 10.201M
- Revenue Q2Q
- N/A
- EPS Q2Q
- 52.37%
- Number of Analysts
- 12
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-1.08%
EPS (3 Months)
-2.11%
Next Earnings Summary
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 167.5M | -100.00% | 13.603M | 6.341M -53.39% | 39.375M 520.96% | 81.222M 106.28% | 257.55M 217.09% | 693.82M 169.39% | 1.174B 69.21% | 1.867B 59.03% | |||
| EBITDA YoY % growth | -107.206M | -94.462M 11.89% | 60.883M 164.45% | -141.78M -332.87% | -155.04M -9.35% | -169.32M -9.21% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -111.026M | -98.551M 11.24% | 57.586M 158.43% | -143.862M -349.82% | -165.663M -15.15% | -194.656M -17.50% | -214.048M -9.96% | -233.944M -9.29% | -141.036M 39.71% | 194.92M 238.21% | 551.35M 182.86% | 955.92M 73.38% | |
| Operating Margin | N/A | N/A | 34.38% | N/A | -1,217.84% | -3,069.80% | -543.61% | -288.03% | -54.76% | 28.09% | 46.96% | 51.20% | |
| EPS YoY % growth | N/A | N/A | N/A | -3.19 86.74% | -3.20 0.88% | -3.47 -8.52% | -2.62 24.70% | -3.00 -14.72% | -1.59 46.98% | 2.02 226.76% | 6.12 203.29% | 9.12 49.01% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.55 52.37% | -0.77 0.20% | -0.76 -14.92% | -0.79 -21.87% | -1.13 -105.87% | -1.10 -42.89% | -1.04 -36.49% | -1.12 -41.96% |
| Revenue Q2Q % growth | 10.201M | 846.6 | 846.6 | 846.6 | -100.00% | -100.00% | -100.00% | -100.00% |
| EBITDA Q2Q % growth | -20.4M 35.48% | -41.82M -19.01% | -44.88M -44.49% | -48.96M -41.18% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -29.641M 1.95% | -41.598M -14.05% | -42.417M -28.67% | -45.252M -23.29% | -65.79M -121.95% | -67.524M -62.33% | -60.894M -43.56% | -67.014M -48.09% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
22.92%
EPS Next 5 Year
13.42%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-70.63%
Revenue Next 5 Year
-8.73%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-105.62%
EBIT Next 5 Year
N/A
MAZE THERAPEUTICS INC / MAZE Forecast FAQ
What are the consensus estimates for MAZE THERAPEUTICS INC (MAZE) next earnings?
The consensus EPS estimate for the next earnings of MAZE THERAPEUTICS INC (MAZE) is -0.55 USD and the consensus revenue estimate is 10.20M USD.
Can you provide the expected long term growth rate for MAZE THERAPEUTICS INC stock?
The expected long term growth rate for MAZE THERAPEUTICS INC (MAZE) is -70.63%.